Peter Coyle - Concepedia

Author

Peter Coyle

Hamad Medical Corporation ORCID

Also Known As

Coyle, PK, Coyle, Peter, P COYLE, P Coyle, P V Coyle, P. COYLE, P. Coyle, P. V. COYLE, P. V. Coyle, P.V Coyle

422

Publications

15.6K

Citations

H-Index

214

Concepts

All Affiliations

Hamad Medical Corporation Qatar University Weill Cornell Medical College in Qatar Ministry of Public Health Queen's University Belfast

About

Peter Coyle is an author at Hamad Medical Corporation specializing in medicine, virology, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	121	5.8K
2	Public Health	24	40	1.7K
3	Health Sciences	15	17	938
4	Engineering	4	4	147
5	Social Sciences	4	4	259

Peter Coyle

236

Publications

12.8K

Citations

H-Index

Page 1

	Year	Citations
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections Heba Altarawneh, Hiam Chemaitelly, Houssein H. Ayoub, New England Journal of Medicine	2022	562
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, Nature Medicine VaccinationVaccine SafetyVaccine DevelopmentCovid-19 PandemicImmunology	2021	460
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar Hiam Chemaitelly, Hadi M. Yassine, Fatiha M. Benslimane, Nature Medicine VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2021	437
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, New England Journal of Medicine	2022	396
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar Hiam Chemaitelly, Houssein H. Ayoub, Sawsan AlMukdad, Nature Communications	2022	231
In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo Rémi Villenave, Surendran Thavagnanam, Séverine Sarlang, Proceedings of the National Academy of Sciences AsthmaRsv PathogenesisRespiratory DiseasesMedicineViral Pathogenesis	2012	204
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy Laith J. Abu‐Raddad, Hiam Chemaitelly, Peter Coyle, EClinicalMedicine	2021	185
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting Laith J. Abu‐Raddad, Hiam Chemaitelly, Joel A. Malek, Clinical Infectious Diseases	2020	176
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, JAMA	2021	174
Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic Laith J. Abu‐Raddad, Hiam Chemaitelly, Houssein H. Ayoub, Scientific Reports	2021	165

Page 1